Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual Meeting
Details for
Title: Target SelectorTM CTC technology demonstrates clinical utility in monitoring treatment response in germ cell tumors (link to abstract)
Session Category/Title: Clinical Research/Liquid Biopsy
Session Date and Time:
Location:
Title: Validation of highly sensitive Target SelectorTM ctDNA assays for EGFR, BRAF, and KRAS mutations (link to abstract)
Session Category/Title: Clinical Research/Diagnostic Biomarkers
Session Date and Time:
Location:
"Capturing and analyzing circulating tumor cells (CTCs) with
"Our collaboration with the
"We are pleased to present data at this year's AACR Annual Meeting highlighting the leading performance of our Target Selector™ assays and the ability to identify actionable biomarkers associated with metastatic cancers," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, and our ability to advance our ongoing work with our collaborators to further demonstrate the clinical utility of our non-invasive liquid biopsy tests, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/biocepts-target-selector-platform-featured-in-two-poster-presentations-at-the-2018-american-association-for-cancer-research-annual-meeting-300614345.html
SOURCE
Investor Contact: LHA Investor Relations; Jody Cain; Jcain@lhai.com; 310-691-7100 OR Media Contact: Trevelino/Keller; Colleen Murphy; cmurphy@trevelinokeller.com; 404-214-0722, Ext. 109